Page 10 - Josh Bartch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: “Facilitating extinction of fear with psilocybin: Model development of biomarkers and mechanisms,” at the University of Maryland School of Medicine in Baltimore, … Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydec...

Mydecine Innovations Group Files Application to list to the NASDAQ Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has submitted a formal application to list its common shares on the NASDAQ Stock Exchange . NASDAQ is the second largest exchange by market capitalization worldwide and is home to many of the world’s best … Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging...

Webcast Information To attend the live video webcast, please register or email KCSA Strategic Communications at [email protected]. About KCSA Strategic Communications KCSA is a fully integrated communications agency specializing in public relations, shareholder communications and social media, with expertise in financial and professional services, technology, healthcare, digital media, cannabis and energy. Since 1969, the Firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The Firm's ...

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has appointed veteran corporate finance and capital markets professional, Gordon Neal to the Board of Directors. Additionally, Dean Ditto has joined the Company as Chief Financial Officer. “MYCO continues to … Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (�...

  The industry is projected to reach a TOTAL VALUE OF US$7B by 2027. Grab your FREE report so you don't miss out on the shroom boom! (As a BONUS, you’ll also get our free psychedelics investing newsletter and investor kits with email updates from curated companies below!*). Enter your email below for instant access: Include me in the Accredited Investor email list Some investment opportunities are limited to accredited investors. Whether you are an accredited investor or not depends on where you live and other criteria. For full details go to https://investingnews.com/accredi...